Recent Articles

• 
  Medical / Drug Development

  Hanmi Pharma Unveils Eight Cancer Drug Candidates in US

  Researchers at Hanmi Pharmaceutical’s R&D Center explain poster presentations on research results for next-generation modality‑based innovative anticancer drugs to participants at the American Association for Cancer Research (AACR 2026) held in San Diego, USA. Courtesy of Hanmi Pharmaceutical Hanmi

  2026.04.28
• 
  Global Business

  SCL Group, Hanaro Foundation Bring K-Health to Indonesia National Hospital

  SCL Group Chairman Lee Kyung-ryul (right) and RSCM Hospital Director Supriyanto Darmorejo pose for a commemorative photo after signing a business agreement. The comprehensive healthcare company SCL Group is establishing a cooperative framework with Indonesia’s National Central General Hospital, acce

  2026.04.28
• 
  Global Business

  Celltrion launches Aptozma, Japan’s first Actemra biosimilar

  Celltrion announced that it has launched the autoimmune disease treatment “Aptozyma” (ingredient name: tocilizumab) in Japan. Aptozyma has been introduced as the first-mover product in Japan’s tocilizumab market, marking the first biosimilar to enter a market dominated by the original drug “Actemra.

  2026.04.28
• 
  Global Business

  United Pharma Deepens Cancer Drug Ties in Philippines

  (From left) Second from left, Setiadi, CEO of GDM; Daxa, Director of Markers; Kang Deok-young, CEO of Korea United Pharm; Aragon, CEO of QualiMed; Kim Gwi-ja, Vice President of Korea United Pharm; Geek, Vice President of QualiMed. Provided by Korea United Pharm A domestic pharmaceutical company has

  2026.04.28
• 
  Medical / Research

  Protein Behind ‘Exercise Without Exercise’ Identified

  Exercise is an effective way to activate brain cells and enhance cognitive function, but it is not easy to practice for those with limited mobility due to aging or disease. A Korean research team has, for the first time in the world, identified the principle by which the brain can be kept young with

  2026.04.28
• 
  Biotech

  Inside hy’s 50-Year-Old R&D Hub for K-Probiotics

  On the 23rd, at the hy Central Research Institute in Yongin, Gyeonggi Province, Probiotics Team Leader Kim Yong-tae explains the process of discovering strains from raw materials. Reporter Kim Hye-rin sinnala8@donga.com “The hy Central Research Institute is not simply a research organization, but a

  2026.04.24
• 
  AI 헬스케어

  KL Cube Builds AI Sign-Language Guide at Seoul Medical Center

  AI sign language guidance service by KLcube installed at Seoul Medical Center. KLcube announced on the 24th that it has introduced an AI sign language avatar guidance service and a real-time sign language interpretation linkage function at Seoul Medical Center. This project has been promoted as part

  2026.04.24
• 
  AI Healthcare

  AI Patent Predicts Responses to Immunotherapy

  An artificial intelligence (AI) technology that predicts the effectiveness of immuno-oncology drugs for each individual patient has been granted a patent. Attention is focusing on whether it can help overcome the current limitation, with treatment success rates hovering around 20%.SCL Science announ

  2026.04.24
• 
  Medical / Drug Development

  Key K-beauty ‘Cica’ emerges as new antibiotic candidate

  Photo=Getty Image Bank. A single ingredient widely used in “K‑beauty” products has emerged as a candidate substance that may be able to suppress antibiotic‑resistant bacteria.The focus is on “madecassic acid,” an extract from Centella asiatica. This ingredient is well known for its skin‑soothing eff

  2026.04.23
• 
  Medical / Research

  Korean Team Uncovers Leukemia Drug’s Cancer-Killing Mechanism

  Research image illustrating the dual role of a leukemia anticancer drug (AI-generated, provided by KAIST) / News1 A Korean research team has identified a new mechanism by which an anticancer drug kills cancer cells.KAIST announced on the 23rd that a joint research team led by Professor Lim Jeong-hoo

  2026.04.23